Prelude Capital Management, LLC Protalix Bio Therapeutics, Inc. Transaction History
Prelude Capital Management, LLC
- $1.12 Billion
- Q3 2025
A detailed history of Prelude Capital Management, LLC transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 49,791 shares of PLX stock, worth $92,611. This represents 0.01% of its overall portfolio holdings.
Number of Shares
49,791
Previous 56,055
11.17%
Holding current value
$92,611
Previous $82,000
35.37%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding PLX
# of Institutions
82Shares Held
10.6MCall Options Held
23.6KPut Options Held
95.4K-
Opaleye Management Inc. Boston, MA2.58MShares$4.8 Million0.96% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.32MShares$2.45 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL902KShares$1.68 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA820KShares$1.52 Million0.0% of portfolio
-
Stratos Wealth Partners, Ltd.500KShares$930,0000.01% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $92.5M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...